[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100600400":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":10,"locations":23,"responsibleParty":45,"collaborators":47,"id":51,"slug":10,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":52,"sex":56,"minAge":57,"maxAge":10,"enrollmentInfo":58,"targetDuration":10,"studyType":61,"phases":10,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":26,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"University of Michigan Rogel Cancer Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational",null,"Patients receive standard care Pluvicto and undergo Lu-177 SPECT\u002FCT scans on study. Patients may also undergo optional 99mTc-SC SPECT\u002FCT scan for bone marrow dosimetry prior to cycle 1. In addition, patients have their medical records reviewed on study.",[13],"Other: Non-Interventional Study",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"Non-Interventional Study","Non-interventional study",[9],[20],{"name":21,"affiliation":5,"role":22},"Yuni K Dewaraja","PRINCIPAL_INVESTIGATOR",[24],{"facility":25,"status":26,"city":27,"state":28,"zip":29,"country":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"University of Michigan Comprehensive Cancer Center","RECRUITING","Ann Arbor","Michigan","48109","United States",{"type":32,"coordinates":33},"Point",[34,35],-83.74088,42.27756,{"lat":35,"lon":34},[38,43],{"name":39,"role":40,"phone":41,"phoneExt":10,"email":42},"James Pool","CONTACT","734-615-7391","jampool@med.umich.edu",{"name":44,"role":22,"phone":10,"phoneExt":10,"email":10},"Yuni K. Dewaraja",{"type":46,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[48],{"name":49,"class":50},"National Cancer Institute (NCI)","NIH","100600400",false,"NCT07096999","SPECT\u002FCT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy","Inclusion Criteria:\n\n* \\* 177Lu-617 PSMA treatment scheduled for mCRPC\n\n  * Clinically stable as determined by the nuclear medicine clinicians\n  * Male\n  * ≥ 18 years of age\n  * Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Patients who are unable to lie flat on the imaging systems long enough to permit imaging protocols to be performed","MALE","18 Years",{"count":59,"type":60},60,"ESTIMATED","OBSERVATIONAL","This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy",[64],"Metastatic Castration-Resistant Prostate Carcinoma",[66,67,68,69,70],"Prostate Cancer","177Lu","PSMA","mCRPC","Radioligand Therapy","2025-07-24",{"date":73,"type":74},"2025-07-31","ACTUAL",{"date":76,"type":74},"2025-01-23",{"date":78,"type":60},"2031-01-23",{"name":5,"class":6},1]